1
|
A new targetry system for production of zirconium-89 radioisotope with Cyclone-30 cyclotron. RADIOCHIM ACTA 2023. [DOI: 10.1515/ract-2022-0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Abstract
In this study, an efficient method for targetry and production of zirconium-89 radioisotope (89Zr) with Cyclone-30 cyclotron was developed. The preparation of a highly pure compressed yttrium oxide target material and design of a target made by copper for better heat transfer was performed. Electrodeposition of target with gold was done to prevent the entry of metallic impurities (copper, zinc and other trace metal elements). Nuclear reaction cross sections for optimization of production with new target and irradiation parameters of the target were evaluated. The prepared 89Zr in the form of [89Zr] Zr-oxalate had high radionuclidic purity (>99.9%) and a low chemical impurity concentration (<0.1 ppm for copper and zinc elements). The yield of 89Zr radioisotope production via the reaction of 89Y(p,n)89Zr was measured to be 77 ± 9.5 MBq/μAh (time of irradiation = 3, the current 20–30 µA). [89Zr] Zr-oxalate specific-activity was in the range 2.319641 × 104–3.479443 × 104 MBq/mmol of Oxalate.
Collapse
|
2
|
Bubenshchikov VB, Larenkov AA, Kodina GE. Preparation of 89Zr Solutions for Radiopharmaceuticals Synthesis. RADIOCHEMISTRY 2021. [DOI: 10.1134/s1066362221030152] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
3
|
Mansel A, Franke K. Production of no-carrier-added 89Zr at an 18 MeV cyclotron, its purification and use in investigations in solvent extraction. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-021-07634-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AbstractThe chemical separation of zirconium from lanthanides by liquid–liquid extraction is challenging but critical for medical and technological applications. Using the example of 89Zr, we optimize the liquid–liquid-extraction process by means of the radiotracer technique. We produced 89Zr by proton irradiation of a metallic yttrium target at a cyclotron. The purification of the radionuclide was performed by a UTEVA resin. 89Zr was separated in no-carrier-added form in a sulfuric acid solution. 89Zr was successfully used in solvent extraction tests with calixarenes for the separation of zirconium from lanthanides. This reaction is suitable for the efficient extraction and purification of lanthanides.
Collapse
|
4
|
Bu L, Sun Y, Han G, Tu N, Xiao J, Wang Q. Outcome Prediction and Evaluation by Imaging the Key Elements of Therapeutic Responses to Cancer Immunotherapies Using PET. Curr Pharm Des 2020; 26:675-687. [PMID: 31465273 DOI: 10.2174/1381612825666190829150302] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Accepted: 08/21/2019] [Indexed: 12/23/2022]
Abstract
Cancer immunotherapy (also known as immuno-oncology), a promising anti-cancer strategy by harnessing the body's own immune system against cancer, has emerged as the "fifth therapeutic pilla" in the field of cancer treatment since surgery, chemotherapy, radiation and targeted therapy. Clinical efficacy of several immunotherapies has been demonstrated in clinical settings, however, only a small subset of patients exhibit dramatic or durable responses, with the highest reported frequency about 10-40% from single-agent PD-L1/PD-1 inhibitors, suggesting the urgent need of consistent objective response biomarkers for monitoring therapeutic response accurately, predicting therapeutic efficacy and selecting responders. Key elements of therapeutic responses to cancer immunotherapies contain the cancer cell response and the alternation of inherent immunological characteristics. Here, we document the literature regarding imaging the key elements of therapeutic responses to cancer immunotherapies using PET. We discussed PET imaging approaches according to different response mechanisms underlying diverse immune-therapeutic categories, and also highlight the ongoing efforts to identify novel immunotherapeutic PET imaging biomarkers. In this article, we show that PET imaging of the key elements of therapeutic responses to cancer immunotherapies using PET can allow for more precise prediction, earlier therapy response monitoring, and improved management. However, all of these strategies need more preclinical study and clinical validation before further development as imaging indicators of the immune response.
Collapse
Affiliation(s)
- Lihong Bu
- PET-CT/MRI Center, Faculty of Radiology and Nuclear Medicine, Wuhan University Renmin Hospital, Wuhan, Hubei, China
| | - Yanqiu Sun
- Department of Radiology, Qinghai Provincial People's Hospital, Xining, Qinghai, China
| | - Guang Han
- Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Ning Tu
- PET-CT/MRI Center, Faculty of Radiology and Nuclear Medicine, Wuhan University Renmin Hospital, Wuhan, Hubei, China
| | - Jiachao Xiao
- PET-CT/MRI Center, Faculty of Radiology and Nuclear Medicine, Wuhan University Renmin Hospital, Wuhan, Hubei, China
| | - Qi Wang
- The 1st Department of Gastrointestinal Surgery, Wuhan University Renmin Hospital, Wuhan, Hubei, China
| |
Collapse
|
5
|
Fenwick AJ, Collins SM, Evans WD, Ferreira KM, Paisey SJ, Robinson AP, Marshall C. Absolute standardisation and determination of the half-life and gamma emission intensities of 89Zr. Appl Radiat Isot 2020; 166:109294. [PMID: 32977243 DOI: 10.1016/j.apradiso.2020.109294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 02/17/2020] [Accepted: 06/11/2020] [Indexed: 11/30/2022]
Abstract
An absolute standardisation of 89Zr was performed alongside determination of gamma emission intensities and half-life. The collected data were evaluated alongside complementary works from previous publications and new recommended nuclear data values are presented including a new evaluated T1/2 = 78.361(25) h and new absolute intensities for gamma transitions resulting from its decay to 89Y. Dial settings for commercially available radionuclide calibrators are also presented and show a relative difference of approximately 3% compared to previously published values.
Collapse
Affiliation(s)
- Andrew J Fenwick
- National Physical Laboratory, Hampton Road, Teddington, UK; Cardiff University, Cardiff, UK.
| | - Sean M Collins
- National Physical Laboratory, Hampton Road, Teddington, UK; The University of Surrey, Guildford, UK
| | - William D Evans
- Cardiff University, Cardiff, UK; Wales Research and Diagnostic Positron Emission Tomography Imaging Centre, School of Medicine, Cardiff University, Cardiff, UK
| | | | - Stephen J Paisey
- Cardiff University, Cardiff, UK; Wales Research and Diagnostic Positron Emission Tomography Imaging Centre, School of Medicine, Cardiff University, Cardiff, UK
| | - Andrew P Robinson
- National Physical Laboratory, Hampton Road, Teddington, UK; The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | - Christopher Marshall
- Cardiff University, Cardiff, UK; Wales Research and Diagnostic Positron Emission Tomography Imaging Centre, School of Medicine, Cardiff University, Cardiff, UK
| |
Collapse
|
6
|
Kiraga Ł, Cerutti G, Braniewska A, Strzemecki D, Sas Z, Boffi A, Savino C, Montemiglio LC, Turnham D, Seaton G, Bonamore A, Clarkson R, Dabkowski AM, Paisey SJ, Taciak B, Kucharzewska P, Rygiel TP, Król M. Biodistribution PET/CT Study of Hemoglobin-DFO- 89Zr Complex in Healthy and Lung Tumor-Bearing Mice. Int J Mol Sci 2020; 21:ijms21144991. [PMID: 32679799 PMCID: PMC7404105 DOI: 10.3390/ijms21144991] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Accepted: 07/11/2020] [Indexed: 01/26/2023] Open
Abstract
Proteins, as a major component of organisms, are considered the preferred biomaterials for drug delivery vehicles. Hemoglobin (Hb) has been recently rediscovered as a potential drug carrier, but its use for biomedical applications still lacks extensive investigation. To further explore the possibility of utilizing Hb as a potential tumor targeting drug carrier, we examined and compared the biodistribution of Hb in healthy and lung tumor-bearing mice, using for the first time 89Zr labelled Hb in a positron emission tomography (PET) measurement. Hb displays a very high conjugation yield in its fast and selective reaction with the maleimide-deferoxamine (DFO) bifunctional chelator. The high-resolution X-ray structure of the Hb-DFO complex demonstrated that cysteine β93 is the sole attachment moiety to the αβ-protomer of Hb. The Hb-DFO complex shows quantitative uptake of 89Zr in solution as determined by radiochromatography. Injection of 0.03 mg of Hb-DFO-89Zr complex in healthy mice indicates very high radioactivity in liver, followed by spleen and lungs, whereas a threefold increased dosage results in intensification of PET signal in kidneys and decreased signal in liver and spleen. No difference in biodistribution pattern is observed between naïve and tumor-bearing mice. Interestingly, the liver Hb uptake did not decrease upon clodronate-mediated macrophage depletion, indicating that other immune cells contribute to Hb clearance. This finding is of particular interest for rapidly developing clinical immunology and projects aiming to target, label or specifically deliver agents to immune cells.
Collapse
Affiliation(s)
- Łukasz Kiraga
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland; (L.K.); (B.T.); (P.K.)
| | - Gabriele Cerutti
- Department of Biochemical Sciences “Alessandro Rossi Fanelli”, Sapienza University of Rome, 00-185 Rome, Italy; (G.C.); (A.B.); (A.B.)
| | - Agata Braniewska
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (A.B.); (D.S.); (Z.S.); (T.P.R.)
| | - Damian Strzemecki
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (A.B.); (D.S.); (Z.S.); (T.P.R.)
| | - Zuzanna Sas
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (A.B.); (D.S.); (Z.S.); (T.P.R.)
| | - Alberto Boffi
- Department of Biochemical Sciences “Alessandro Rossi Fanelli”, Sapienza University of Rome, 00-185 Rome, Italy; (G.C.); (A.B.); (A.B.)
| | - Carmelinda Savino
- Institute of Molecular Biology and Pathology, National Research Council, 00-185 Rome, Italy; (C.S.); (L.C.M.)
| | - Linda Celeste Montemiglio
- Institute of Molecular Biology and Pathology, National Research Council, 00-185 Rome, Italy; (C.S.); (L.C.M.)
| | - Daniel Turnham
- European Cancer Stem Cell Research Institute (ECSCRI), School of Biosciences, Haydn Ellis Building, Cardiff University, Cardiff CF24 4HQ, Wales, UK; (D.T.); (G.S.); (R.C.)
| | - Gillian Seaton
- European Cancer Stem Cell Research Institute (ECSCRI), School of Biosciences, Haydn Ellis Building, Cardiff University, Cardiff CF24 4HQ, Wales, UK; (D.T.); (G.S.); (R.C.)
| | - Alessandra Bonamore
- Department of Biochemical Sciences “Alessandro Rossi Fanelli”, Sapienza University of Rome, 00-185 Rome, Italy; (G.C.); (A.B.); (A.B.)
| | - Richard Clarkson
- European Cancer Stem Cell Research Institute (ECSCRI), School of Biosciences, Haydn Ellis Building, Cardiff University, Cardiff CF24 4HQ, Wales, UK; (D.T.); (G.S.); (R.C.)
| | - Adam M. Dabkowski
- Wales Research & Diagnostic PET Imaging Centre (PETIC), School of Medicine, Heath Park, Cardiff University, Cardiff CF14 4XN, Wales, UK; (A.M.D.); (S.J.P.)
| | - Stephen J. Paisey
- Wales Research & Diagnostic PET Imaging Centre (PETIC), School of Medicine, Heath Park, Cardiff University, Cardiff CF14 4XN, Wales, UK; (A.M.D.); (S.J.P.)
| | - Bartłomiej Taciak
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland; (L.K.); (B.T.); (P.K.)
| | - Paulina Kucharzewska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland; (L.K.); (B.T.); (P.K.)
| | - Tomasz P. Rygiel
- Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; (A.B.); (D.S.); (Z.S.); (T.P.R.)
| | - Magdalena Król
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland; (L.K.); (B.T.); (P.K.)
- Correspondence: ; Tel.: +48-22-59-362-59
| |
Collapse
|
7
|
Abstract
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89Zr-Df-pertuzumab and 89Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
Collapse
Affiliation(s)
- Weijun Wei
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, 1111 Highland Avenue, Room 7137, Madison, Wisconsin 53705, United States
| | - Zachary T Rosenkrans
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
| | - Jianjun Liu
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
| | - Gang Huang
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
- Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China
| | - Quan-Yong Luo
- Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, 1111 Highland Avenue, Room 7137, Madison, Wisconsin 53705, United States
- Department of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705, United States
| |
Collapse
|
8
|
Assessing the interactions between radiotherapy and antitumour immunity. Nat Rev Clin Oncol 2019; 16:729-745. [PMID: 31243334 DOI: 10.1038/s41571-019-0238-9] [Citation(s) in RCA: 163] [Impact Index Per Article: 32.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/28/2019] [Indexed: 12/17/2022]
Abstract
Immunotherapy, specifically the introduction of immune checkpoint inhibitors, has transformed the treatment of cancer, enabling long-term tumour control even in individuals with advanced-stage disease. Unfortunately, only a small subset of patients show a response to currently available immunotherapies. Despite a growing consensus that combining immune checkpoint inhibitors with radiotherapy can increase response rates, this approach might be limited by the development of persistent radiation-induced immunosuppression. The ultimate goal of combining immunotherapy with radiotherapy is to induce a shift from an ineffective, pre-existing immune response to a long-lasting, therapy-induced immune response at all sites of disease. To achieve this goal and enable the adaptation and monitoring of individualized treatment approaches, assessment of the dynamic changes in the immune system at the patient level is essential. In this Review, we summarize the available clinical data, including forthcoming methods to assess the immune response to radiotherapy at the patient level, ranging from serum biomarkers to imaging techniques that enable investigation of immune cell dynamics in patients. Furthermore, we discuss modelling approaches that have been developed to predict the interaction of immunotherapy with radiotherapy, and highlight how they could be combined with biomarkers of antitumour immunity to optimize radiotherapy regimens and maximize their synergy with immunotherapy.
Collapse
|
9
|
Watson HA, Durairaj RRP, Ohme J, Alatsatianos M, Almutairi H, Mohammed RN, Vigar M, Reed SG, Paisey SJ, Marshall C, Gallimore A, Ager A. L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy. Front Immunol 2019; 10:1321. [PMID: 31249570 PMCID: PMC6582763 DOI: 10.3389/fimmu.2019.01321] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Accepted: 05/24/2019] [Indexed: 12/11/2022] Open
Abstract
The homing molecule, L-selectin (CD62L), is commonly used as a T cell activation marker, since expression is downregulated following engagement of the T cell receptor. Studies in mice have shown that CD62L+ central memory T cells are better at controlling tumor growth than CD62L- effector memory T cells, while L-selectin knockout T cells are poor at controlling tumor growth. Here, we test the hypothesis that T cells expressing genetically modified forms of L-selectin that are maintained following T cell activation (L-selectin enhanced T cells) are better at controlling tumor growth than wild type T cells. Using mouse models of adoptive cell therapy, we show that L-selectin enhancement improves the efficacy of CD8+ T cells in controlling solid and disseminated tumor growth. L-selectin knockout T cells had no effect. Checkpoint blockade inhibitors synergized with wild type and L-selectin enhanced T cells but had no effect in the absence of T cell transfers. Reduced tumor growth by L-selectin enhanced T cells correlated with increased frequency of CD8+ tumor infiltrating T cells 21 days after commencing therapy. Longitudinal tracking of Zirconium-89 (89Zr) labeled T cells using PET-CT showed that transferred T cells localize to tumors within 1 h and accumulate over the following 7 days. L-selectin did not promote T cell homing to tumors within 18 h of transfer, however the early activation marker CD69 was upregulated on L-selectin positive but not L-selectin knockout T cells. L-selectin positive and L-selectin knockout T cells homed equally well to tumor-draining lymph nodes and spleens. CD69 expression was upregulated on both L-selectin positive and L-selectin knockout T cells but was significantly higher on L-selectin expressing T cells, particularly in the spleen. Clonal expansion of isolated L-selectin enhanced T cells was slower, and L-selectin was linked to expression of proliferation marker Ki67. Together these findings demonstrate that maintaining L-selectin expression on tumor-specific T cells offers an advantage in mouse models of cancer immunotherapy. The beneficial role of L-selectin is unrelated to its' well-known role in T cell homing and, instead, linked to activation of therapeutic T cells inside tumors. These findings suggest that L-selectin may benefit clinical applications in T cell selection for cancer therapy and for modifying CAR-T cells to broaden their clinical scope.
Collapse
Affiliation(s)
- H. Angharad Watson
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Ruban R. P. Durairaj
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Julia Ohme
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Markella Alatsatianos
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Hanan Almutairi
- PET Imaging Centre, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Rebar N. Mohammed
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Miriam Vigar
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Sophie G. Reed
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Stephen J. Paisey
- PET Imaging Centre, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Christopher Marshall
- PET Imaging Centre, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | - Awen Gallimore
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
- Systems Immunity Research Institute, Cardiff University, Cardiff, United Kingdom
| | - Ann Ager
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom
- Systems Immunity Research Institute, Cardiff University, Cardiff, United Kingdom
| |
Collapse
|
10
|
La MT, Tran VH, Kim HK. Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies. Nucl Med Mol Imaging 2019; 53:115-124. [PMID: 31057683 DOI: 10.1007/s13139-019-00584-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 01/14/2019] [Accepted: 01/17/2019] [Indexed: 02/07/2023] Open
Abstract
Radiometals have been commonly used in medical applications, and utilization of such metals continues to be an attractive research area. In particular, a variety of radiometals have been developed and implemented for molecular imaging. For such applications, 89Zr has been one of the most interesting radiometals currently used for tumor targeting. Several chemical ligands were developed as 89Zr chelators, and new coordinating methods have also been developed more recently. In addition, immuno-positron emission tomography (PET) studies using 89Zr-labeled monoclonal antibodies have been performed by several scientists. In this review, recent advances to the coordination of 89Zr and the utilization of 89Zr in PET studies are described.
Collapse
Affiliation(s)
- Minh Thanh La
- Department of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Cyclotron Research Center, Biomedical Research Institute, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk 54907 Republic of Korea
| | - Van Hieu Tran
- Department of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Cyclotron Research Center, Biomedical Research Institute, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk 54907 Republic of Korea
| | - Hee-Kwon Kim
- Department of Nuclear Medicine, Molecular Imaging & Therapeutic Medicine Research Center, Cyclotron Research Center, Biomedical Research Institute, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk 54907 Republic of Korea
| |
Collapse
|
11
|
Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treat Rev 2018; 70:232-244. [DOI: 10.1016/j.ctrv.2018.09.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 09/20/2018] [Accepted: 09/21/2018] [Indexed: 01/04/2023]
|
12
|
Abstract
The recent clinical success of cancer immunotherapy has renewed interest in the development of tools to image the immune system. In general, immunotherapies attempt to enable the body's own immune cells to seek out and destroy malignant disease. Molecular imaging of the cells and molecules that regulate immunity could provide unique insight into the mechanisms of action, and failure, of immunotherapies. In this article, we will provide a comprehensive overview of the current state-of-the-art immunoimaging toolbox with a focus on imaging strategies and their applications toward immunotherapy.
Collapse
Affiliation(s)
- Aaron T Mayer
- Department of Bioengineering, Stanford University, Stanford, California; and
| | - Sanjiv S Gambhir
- Department of Bioengineering, Stanford University, Stanford, California; and
- Department of Radiology, Department of Materials Science and Engineering, Molecular Imaging Program at Stanford, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, California
| |
Collapse
|
13
|
Optimized anion exchange column isolation of zirconium-89 (89Zr) from yttrium cyclotron target: Method development and implementation on an automated fluidic platform. J Chromatogr A 2018. [DOI: 10.1016/j.chroma.2018.02.053] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
14
|
Production and radiochemical separation of a potential immuno-PET imaging agent 89Zr from proton irradiated natY target. J Radioanal Nucl Chem 2017. [DOI: 10.1007/s10967-017-5316-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
15
|
Tang Y, Li S, Yang Y, Chen W, Wei H, Wang G, Yang J, Liao J, Luo S, Liu N. A simple and convenient method for production of 89Zr with high purity. Appl Radiat Isot 2016; 118:326-330. [PMID: 27744256 DOI: 10.1016/j.apradiso.2016.09.024] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2016] [Revised: 09/24/2016] [Accepted: 09/24/2016] [Indexed: 11/15/2022]
Abstract
A simple and convenient method for radiochemical separation 89Zr with no harmful substance was explored. The separated 89Zr was found to be [89Zr]Zr-chloride, and the recovery of the radioactivity was 85%±3% with high radionuclidic purity (99.99%). The yields of 89Zr via the reaction of (p, n) or (d, 2n) on Y target were also evaluated on CS-30 cyclotron, indicating the latter was more favorable for the production of 89Zr with a yield of 58±4 MBq/μA·h.
Collapse
Affiliation(s)
- Yu Tang
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, P. R. China
| | - Shuntao Li
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, P. R. China
| | - Yuanyou Yang
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, P. R. China.
| | - Wen Chen
- Institute of Nuclear Physics and Chemistry, CAEP, Mianyang 621900, P. R. China
| | - Hongyuan Wei
- Institute of Nuclear Physics and Chemistry, CAEP, Mianyang 621900, P. R. China
| | - Guanquan Wang
- Institute of Nuclear Physics and Chemistry, CAEP, Mianyang 621900, P. R. China
| | - Jijun Yang
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, P. R. China
| | - Jiali Liao
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, P. R. China
| | - Shunzhong Luo
- Institute of Nuclear Physics and Chemistry, CAEP, Mianyang 621900, P. R. China
| | - Ning Liu
- Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, P. R. China.
| |
Collapse
|
16
|
Lee HW, Gangadaran P, Kalimuthu S, Ahn BC. Advances in Molecular Imaging Strategies for In Vivo Tracking of Immune Cells. BIOMED RESEARCH INTERNATIONAL 2016; 2016:1946585. [PMID: 27725934 PMCID: PMC5048043 DOI: 10.1155/2016/1946585] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 08/12/2016] [Accepted: 08/23/2016] [Indexed: 01/25/2023]
Abstract
Tracking of immune cells in vivo is a crucial tool for development and optimization of cell-based therapy. Techniques for tracking immune cells have been applied widely for understanding the intrinsic behavior of immune cells and include non-radiation-based techniques such as optical imaging and magnetic resonance imaging (MRI), radiation-based techniques such as computerized tomography (CT), and nuclear imaging including single photon emission computerized tomography (SPECT) and positron emission tomography (PET). Each modality has its own strengths and limitations. To overcome the limitations of each modality, multimodal imaging techniques involving two or more imaging modalities are actively applied. Multimodal techniques allow integration of the strengths of individual modalities. In this review, we discuss the strengths and limitations of currently available preclinical in vivo immune cell tracking techniques and summarize the value of immune cell tracking in the development and optimization of immune cell therapy for various diseases.
Collapse
Affiliation(s)
- Ho Won Lee
- Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
| | - Prakash Gangadaran
- Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
| | - Senthilkumar Kalimuthu
- Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
| | - Byeong-Cheol Ahn
- Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital, Daegu, Republic of Korea
| |
Collapse
|
17
|
Semi-automated production of 89 Zr-oxalate/ 89 Zr-chloride and the potential of 89 Zr-chloride in radiopharmaceutical compounding. Appl Radiat Isot 2016; 107:317-322. [DOI: 10.1016/j.apradiso.2015.11.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 11/07/2015] [Indexed: 11/20/2022]
|
18
|
Tailoring medium energy proton beam to induce low energy nuclear reactions in 86SrCl2 for production of PET radioisotope 86Y. Appl Radiat Isot 2015; 101:20-26. [DOI: 10.1016/j.apradiso.2015.02.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Accepted: 02/23/2015] [Indexed: 11/18/2022]
|
19
|
Price EW, Zeglis BM, Lewis JS, Adam MJ, Orvig C. H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. Dalton Trans 2014; 43:119-31. [PMID: 24104523 PMCID: PMC3872121 DOI: 10.1039/c3dt51940f] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The acyclic chelator H6phospa and the bifunctional derivative p-SCN-Bn-H6phospa have been synthesized using nosyl protection chemistry and evaluated with (89)Zr, (111)In, and (177)Lu. The p-SCN-Bn-H6phospa derivative was successfully conjugated to trastuzumab with isotopic dilution assays indicating 3.3 ± 0.1 chelates per antibody and in vitro cellular binding assays indicating an immunoreactivity value of 97.9 ± 2.6%. Radiolabeling of the H6phospa-trastuzumab immunoconjugate was achieved with (111)In in 70-90% yields at room temperature in 30 minutes, while (177)Lu under the same conditions produced more inconsistent yields of 40-80%. Stability experiments in human serum revealed the (111)In-phospa-trastuzumab complex to be 52.0 ± 5.3% intact after 5 days at 37 °C, while the (177)Lu-phospa-trastuzumab to be only 2.0 ± 0.3% intact. Small animal SPECT/CT imaging using mice bearing subcutaneous SKOV-3 ovarian cancer xenografts was performed, and it was found that (111)In-phospa-trastuzumab successfully identified and delineated small (~2 mm in diameter) tumors from surrounding tissues, despite visible uptake in the kidneys and bone due to moderate chelate instability. As predicted from stability assays in serum, the (177)Lu-phospa-trastuzumab conjugate served as a negative control and displayed no tumor uptake, with high uptake in bones indicating rapid and complete radiometal dissociation and suggesting a potential application of H6phospa in transient lanthanide chelation for bone-delivery. Radiolabeling with (89)Zr was attempted, but even with elevated temperatures of 37 °C, the maximum observed radiometal incorporation over 18 hours was 12%. It can be concluded from this work that H6phospa is not superior to the previously studied H4octapa for use with (111)In and (177)Lu, but improvements in (89)Zr radiolabeling were observed over H4octapa, suggesting H6phospa to be an excellent starting point for elaboration of (89)Zr-based radiopharmaceutical development. To our knowledge, H6phospa is the best desferrioxamine alternative for (89)Zr radiolabeling to be studied to date.
Collapse
Affiliation(s)
- Eric W. Price
- Medicinal Inorganic Chemistry Group, Department of
Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British
Columbia, Canada, V6T 1Z1. Telephone: (604) 822-4449. Fax: (604) 822-2847
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia,
Canada, V6T 2A3. Telephone: (604) 222-7527. Fax: (604) 222-1074
| | - Brian M. Zeglis
- Memorial Sloan-Kettering Cancer Center (MSKCC), Memorial
Hospital, 1275 York Avenue, New York, New York, 10065, United States. Telephone:
(646) 888-3038
| | - Jason S. Lewis
- Memorial Sloan-Kettering Cancer Center (MSKCC), Memorial
Hospital, 1275 York Avenue, New York, New York, 10065, United States. Telephone:
(646) 888-3038
| | - Michael J. Adam
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia,
Canada, V6T 2A3. Telephone: (604) 222-7527. Fax: (604) 222-1074
| | - Chris Orvig
- Medicinal Inorganic Chemistry Group, Department of
Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British
Columbia, Canada, V6T 1Z1. Telephone: (604) 822-4449. Fax: (604) 822-2847
| |
Collapse
|
20
|
|
21
|
Fischer G, Seibold U, Schirrmacher R, Wängler B, Wängler C. (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules 2013; 18:6469-90. [PMID: 23736785 PMCID: PMC6269898 DOI: 10.3390/molecules18066469] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Revised: 05/24/2013] [Accepted: 05/29/2013] [Indexed: 12/12/2022] Open
Abstract
Molecular imaging-and especially Positron Emission Tomography (PET)-is of increasing importance for the diagnosis of various diseases and thus is experiencing increasing dissemination. Consequently, there is a growing demand for appropriate PET tracers which allow for a specific accumulation in the target structure as well as its visualization and exhibit decay characteristics matching their in vivo pharmacokinetics. To meet this demand, the development of new targeting vectors as well as the use of uncommon radionuclides becomes increasingly important. Uncommon nuclides in this regard enable the utilization of various selectively accumulating bioactive molecules such as peptides, antibodies, their fragments, other proteins and artificial structures for PET imaging in personalized medicine. Among these radionuclides, 89Zr (t1/2 = 3.27 days and mean Eβ+ = 0.389 MeV) has attracted increasing attention within the last years due to its favorably long half-life, which enables imaging at late time-points, being especially favorable in case of slowly-accumulating targeting vectors. This review outlines the recent developments in the field of 89Zr-labeled bioactive molecules, their potential and application in PET imaging and beyond, as well as remaining challenges.
Collapse
Affiliation(s)
- Gabriel Fischer
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim 68167, Germany; E-Mails: (G.F.); (W.S.)
- University Hospital Munich, Department of Nuclear Medicine, Ludwig Maximilians-University, Munich 81377, Germany
| | - Uwe Seibold
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim 68167, Germany; E-Mails: (G.F.); (W.S.)
- Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim 68167, Germany; E-Mail:
| | - Ralf Schirrmacher
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada; E-Mail:
| | - Björn Wängler
- Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim 68167, Germany; E-Mail:
| | - Carmen Wängler
- Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim 68167, Germany; E-Mails: (G.F.); (W.S.)
- University Hospital Munich, Department of Nuclear Medicine, Ludwig Maximilians-University, Munich 81377, Germany
- Author to whom correspondence should be addressed: E-Mail: ; Tel.: +49-621-383-3761; Fax: +49-621-383-1910
| |
Collapse
|
22
|
Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nucl Med Biol 2012; 40:3-14. [PMID: 22998840 DOI: 10.1016/j.nucmedbio.2012.08.004] [Citation(s) in RCA: 294] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Revised: 08/07/2012] [Accepted: 08/12/2012] [Indexed: 02/08/2023]
Abstract
The advent of antibody-based cancer therapeutics has led to the concomitant rise in the development of companion diagnostics for these therapies, particularly nuclear imaging agents. A number of radioisotopes have been employed for antibody-based PET and SPECT imaging, notably ⁶⁴Cu, ¹²⁴I, ¹¹¹In, and (99m)Tc; in recent years, however, the field has increasingly focused on ⁸⁹Zr, a radiometal with near ideal physical and chemical properties for immunoPET imaging. In the review at hand, we seek to provide a comprehensive portrait of the current state of ⁸⁹Zr radiochemical and imaging research, including work into the production and purification of the isotope, the synthesis of new chelators, the development of new bioconjugation strategies, the creation of novel ⁸⁹Zr-based agents for preclinical imaging studies, and the translation of ⁸⁹Zr-labeled radiopharmaceuticals to the clinic. Particular attention will also be dedicated to emerging trends in the field, ⁸⁹Zr-based imaging applications using vectors other than antibodies, the comparative advantages and limitations of ⁸⁹Zr-based imaging compared to that with other isotopes, and areas that would benefit from more extensive investigation. At bottom, it is hoped that this review will provide both the experienced investigator and new scientist with a full and critical overview of this exciting and fast-developing field.
Collapse
Affiliation(s)
- Melissa A Deri
- Department of Radiology and the Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | |
Collapse
|
23
|
Quintero NY, Restrepo G, Cohen IM. Chemotopological study of positron emitter radionuclides used in PET diagnostic imaging: physical, physico-chemical, dosimetric, quantum and nuclear properties. J Radioanal Nucl Chem 2012. [DOI: 10.1007/s10967-012-1919-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
24
|
Horn F, Heinekamp T, Kniemeyer O, Pollmächer J, Valiante V, Brakhage AA. Systems biology of fungal infection. Front Microbiol 2012; 3:108. [PMID: 22485108 PMCID: PMC3317178 DOI: 10.3389/fmicb.2012.00108] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2011] [Accepted: 03/05/2012] [Indexed: 12/26/2022] Open
Abstract
Elucidation of pathogenicity mechanisms of the most important human-pathogenic fungi, Aspergillus fumigatus and Candida albicans, has gained great interest in the light of the steadily increasing number of cases of invasive fungal infections. A key feature of these infections is the interaction of the different fungal morphotypes with epithelial and immune effector cells in the human host. Because of the high level of complexity, it is necessary to describe and understand invasive fungal infection by taking a systems biological approach, i.e., by a comprehensive quantitative analysis of the non-linear and selective interactions of a large number of functionally diverse, and frequently multifunctional, sets of elements, e.g., genes, proteins, metabolites, which produce coherent and emergent behaviors in time and space. The recent advances in systems biology will now make it possible to uncover the structure and dynamics of molecular and cellular cause-effect relationships within these pathogenic interactions. We review current efforts to integrate omics and image-based data of host-pathogen interactions into network and spatio-temporal models. The modeling will help to elucidate pathogenicity mechanisms and to identify diagnostic biomarkers and potential drug targets for therapy and could thus pave the way for novel intervention strategies based on novel antifungal drugs and cell therapy.
Collapse
Affiliation(s)
- Fabian Horn
- Systems Biology/Bioinformatics, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll InstituteJena, Germany
| | - Thorsten Heinekamp
- Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll InstituteJena, Germany
| | - Olaf Kniemeyer
- Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll InstituteJena, Germany
| | - Johannes Pollmächer
- Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll InstituteJena, Germany
| | - Vito Valiante
- Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll InstituteJena, Germany
| | - Axel A. Brakhage
- Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll InstituteJena, Germany
- Department of Microbiology and Molecular Biology, Institute of Microbiology, Friedrich Schiller UniversityJena, Germany
| |
Collapse
|
25
|
Thieme S, Walther M, Pietzsch HJ, Henniger J, Preusche S, Mäding P, Steinbach J. Module-assisted preparation of 64Cu with high specific activity. Appl Radiat Isot 2012; 70:602-8. [DOI: 10.1016/j.apradiso.2012.01.019] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Revised: 12/22/2011] [Accepted: 01/22/2012] [Indexed: 11/16/2022]
|
26
|
|
27
|
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol 2012; 33:607-15. [PMID: 22270450 PMCID: PMC3342498 DOI: 10.1007/s13277-012-0316-4] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2011] [Accepted: 01/03/2012] [Indexed: 10/26/2022] Open
Abstract
During the last decade, the discovery of critical tumor targets has boosted the design of targeted therapeutic agents with monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) receiving most of the attention. Immuno-positron emission tomography (immuno-PET) and TKI-PET, the in vivo tracking and quantification of mAbs and TKIs biodistribution with PET, are exciting novel options for better understanding of the in vivo behavior and efficacy of these targeted drugs in individual patients and for more efficient drug development. Very recently, current good manufacturing practice compliant procedures for labeling of mAbs with positron emitters have been described, as well as the preparation of some radiolabeled TKIs, while the first proof of principle studies has been performed in patients. In this review, technical developments in immuno-PET and TKI-PET are described, and their clinical potential is discussed. An overview is provided for the most appealing preclinical immuno-PET and TKI-PET studies, as well as the first clinical achievements with these emerging technologies.
Collapse
|